Investors

Our team possesses the scientific and industry know-how needed to accomplish our mission of fundamentally changing how autoimmune diseases are treated. We are proud to be partnered with investors that believe in our team and mission.

Istock 1134045124 Aspect Ratio 388 406
Dscf4411 2 Aspect Ratio 276 264
8vc Logo Aspect Ratio 408 322
8VC
Alexandria Aspect Ratio 408 322
Alexandria Venture Investments
Ally Bridge Group Aspect Ratio 408 322
Ally Bridge Group
Arch Venture Partners Aspect Ratio 408 322
Arch Venture Partners
Arrowmark Partners Aspect Ratio 408 322
Arrowmark Partners
Avidity Partners Aspect Ratio 408 322
Casdin Capital Aspect Ratio 408 322
Casdin Capital
Deep Track Capital Aspect Ratio 408 322
Deep Track Capital
Frazier Healthcare Partners Aspect Ratio 408 322
Frazier Life Sciences
Gv Aspect Ratio 408 322
Google Ventures
Janus Henderson Aspect Ratio 408 322
Janus Henderson
Lifeforce Capital Aspect Ratio 408 322
Lifeforce Capital
Jdrf Aspect Ratio 408 322
T1D Fund
Lilly Ventures Aspect Ratio 408 322
Lilly Asia Ventures
Lyell Aspect Ratio 408 322
Lyell
Mirae Asset Aspect Ratio 408 322
Mirae Asset Global Investments
Octagon Capital Partners Aspect Ratio 408 322
Octagon Investment
Osage Aspect Ratio 408 322
Osage University Partners
Piper Sandler Aspect Ratio 408 322
Piper Sandler
Timefolio 1 Aspect Ratio 408 322
Timefolio Capital
Vertex Aspect Ratio 408 322
Vertex Ventures HC